Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Income from Continuing Operations of 4970000.0 for Q1 2026, up 63.4% year-over-year from 3041627.46 in Q1 2025, and down 117.35% quarter-over-quarter from 28648000.0 in Q4 2025.
Powered by 
Analysis
Theravance Biopharma (TBPH) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Income from Continuing Operations for 14 consecutive years, with 4970000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 63.4% year-over-year to 4970000.0; the TTM figure through Mar 2026 stood at 82128000.0 (up 240.79% YoY), while the FY2025 annual figure was 73519000.0, up 230.31% from the prior year.
- Income from Continuing Operations fell to 4970000.0 in Q1 2026 per TBPH's latest filing, from 28648000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 54835000.0 in Q2 2025 and bottomed at 40259000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 7804647.06 across 5 years, with a median of 13579000.0 in 2025.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 192.8% — and 2025, when it soared 431.75%.
- Theravance Biopharma's Income from Continuing Operations stood at 14256000.0 in 2022, then soared by 62.8% to 5303000.0 in 2023, then tumbled by 192.8% to 15527000.0 in 2024, then jumped by 284.5% to 28648000.0 in 2025, then sank by 117.35% to 4970000.0 in 2026.
- Business Quant data shows TBPH's Income from Continuing Operations at 4970000.0 in Q1 2026, 28648000.0 in Q4 2025, and 3615000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Theravance Biopharma | 882.47 Mn | 494.81 Mn | - | -5.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.90 Mn |
| Mar 31, 2026 | -4.93 Mn |
| Dec 31, 2025 | 49.51 Mn |
| Sep 30, 2025 | 3.62 Mn |
| Jun 30, 2025 | 54.84 Mn |
| Mar 31, 2025 | -13.58 Mn |
| Dec 31, 2024 | -25.11 Mn |
| Sep 30, 2024 | -12.70 Mn |
| Jun 30, 2024 | -16.53 Mn |
| Mar 31, 2024 | -11.66 Mn |
| Dec 31, 2023 | -8.51 Mn |
| Sep 30, 2023 | -8.95 Mn |
| Jun 30, 2023 | -15.65 Mn |
| Mar 31, 2023 | -22.09 Mn |
| Dec 31, 2022 | 164.75 Mn |
| Sep 30, 2022 | -15.52 Mn |
| Jun 30, 2022 | -22.79 Mn |
| Mar 31, 2022 | -40.26 Mn |
| Dec 31, 2021 | -57.77 Mn |
| Sep 30, 2021 | -55.91 Mn |